Log on / register
Feedback | Support | My details
Open AccessHighly AccessStudy protocol

The CRASH trial protocol (Corticosteroid randomisation after significant head injury) [ISRCTN74459797]

The CRASH trial management group email for the CRASH trial collaborators

CRASH Co-ordinating Centre, FREEPOST LON 14211, London, WC1B 3BR, UK

author email corresponding author email

BMC Emergency Medicine 2001, 1:1doi:10.1186/1471-227X-1-1

Published: 11 June 2001

Abstract

Background

Worldwide, millions of people are treated each year for significant head injury. A substantial proportion die, and many more are disabled. If short term corticosteroid infusion could be reliably shown to reduce these risks by just a few percent then this might affect the treatment of a few hundred thousand patients a year, protecting thousands from death or long term disability.

Study design

CRASH is a large simple, placebo-controlled trial of the effects of a 48-hour infusion of corticosteroids on death and on neurological disability, among adults with head injury and some impairment of consciousness. Head injured patients with impaired consciousness who are judged to be 16 years or older are eligible if the responsible doctor is, for any reason, substantially uncertain whether or not to use corticosteroids.

Organisation

The CRASH trial will determine reliably the effects on death and disability of a short corticosteroid infusion following significant head injury. To detect or refute improvements of only a few percent in outcome, many thousands of acute head injury patients must be randomised between control and steroid infusions. Such large numbers will be possible only if hundreds of doctors and nurses can collaborate in the participating emergency departments. Since they are busy, and working in emergency situations, the trial involves them in almost no extra work: no special investigations or changes to usual management are required, and data collection is absolutely minimal. The trial is on-going and new collaborators are welcome. Further information about the trial is available at http://www.crash.lshtm.ac.uk webcite


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.